SSTR2 and neoplasm: Upon observation of a cytokine surge, patients receiving tumor-targeted T cells expressing SSTR2 could be imaged via PET/CT to examine the T cell distribution profile and determine whether they are expanding at the tumor site, or, if they are expanding away from the tumor, thus indicating the onset of off-tumor toxicities.